Bolt biotherapeutics provides update on bdc-4182 and extends cash runway into 2027

Redwood city, calif., oct. 01, 2025 (globe newswire) -- bolt biotherapeutics (nasdaq: bolt), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing phase 1 dose escalation study of bdc-4182, a next-generation boltbody™ isac clinical candidate targeting claudin 18.2, a clinically validated target in oncology. a strong immune response was observed at the initial dose levels and the company is in the process of modifying the clinical trial protocol to allow for step-up dosing, which has been successfully used commercially for t-cell engagers. bdc-4182 preclinical data supports this approach.
BDC Ratings Summary
BDC Quant Ranking